Clinical trial
Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
NCT00095329 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00095329 |
|---|---|
| Title | Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor |
| Official title | A Phase I/II, Open-Label Pilot Trial to Evaluate the Safety of Rapamune (Sirolimus) in Patients With Multiple Sclerosis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Autoimmunity Centers of Excellence |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis (MS) - Relapsing-remitting |
| Intervention type | Biological |
| Interventions | sirolimus |
| Enrollment | 14 |
| Start date | May 1, 2003 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Nov 3, 2004 |
| Last update posted | Sep 22, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: